Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib for Patients With Relapsed, Refractory or High-Risk Untreated Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Feb 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.
- 01 Feb 2017 Status changed from not yet recruiting to recruiting.
- 30 Jul 2016 New trial record